ReviewCurrent neurology and neuroscience reports2005
Targeted molecular therapy of malignant gliomas.
Review in Current neurology and neuroscience reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 57 citations in OpenAlex.
- Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.Neuro-oncology · 2008Trial
- Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.Neuro-oncology · 2007Trial
- Targeting Glioblastoma: The Current State of Different Therapeutic Approaches.Current neuropharmacology · 2021Review
- Natural dietary compound naringin inhibits glioblastoma cancer neoangiogenesis.BMC pharmacology & toxicology · 2020Article
- Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches.Contemporary oncology (Poznan, Poland) · 2020Review
- Bioinformatics Analysis of Key Genes and Pathways for Medulloblastoma as a Therapeutic TargetAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Article
- Neural stem cells secrete factors facilitating brain regeneration upon constitutive Raf-Erk activation.Scientific reports · 2016Article
- Effect of brefelamide on HGF-induced survival of 1321N1 human astrocytoma cells.In vitro cellular & developmental biology. Animal · 2016Article
- Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.Genes & cancer · 2013Review
- Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling.Cancer research · 2012Article
- Overexpression of SSAT by DENSPM treatment induces cell detachment and apoptosis in glioblastoma.Oncology reports · 2012Article
- Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC-ι-mediated signaling cascade in glioblastoma.Carcinogenesis · 2012Article
- Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.The Lancet. Neurology · 2010Review
- Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.Neuro-oncology · 2009Article
- Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells.Journal of experimental therapeutics & oncology · 2009Article
- Biomarkers of clinical responsiveness in brain tumor patients : progress and potential.Molecular diagnosis & therapy · 2008Review
- Medical management of patients with brain tumors.Journal of neuro-oncology · 2006Review
- Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor andAsian journal of neurosurgeryArticle
Corrections and comments
- Reprinted as
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant gliomas are the most common form of primary brain tumors in adults. Despite advances in diagnosis and standard therapies such as surgery, radiation, and chemotherapy, the prognosis remains poor. Recent scientific advances have enhanced our understanding of the biology of gliomas and the role of tyrosine kinase receptors and signal transduction pathways in tumor initiation and maintenance, such as the epidermal growth factor receptors, platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and the Ras/Raf/mitogen-activated protein (MAP)-kinase and phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways. Novel targeted drugs such as small molecular inhibitors of these receptors and signaling pathways are showing some activity in initial studies. As we learn more about these drugs and how to optimize their use as single agents and in combination with radiation, chemotherapy, and other targeted molecular agents, they will likely play an increasing role in the management of this devastating disease. This review summarizes the current results with targeted molecular agents in malignant gliomas and strategies under evaluation to increase their effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.